Keywords: cash, shortfall, delays, trial, novacea, aq4n, drugmaker

Cash shortfall delays trial of Novacea's AQ4N

Article | 14 January 2008

Print This

US drugmaker Novacea has decided to scale back on its clinical development activities for AQ4N (banoxantrone), an investigational anti-cancer ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in